Cyclerion Therapeutics Stock Price To Earning
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Cyclerion Therapeutics' long-term financial health and intrinsic value.
Cyclerion | Build AI portfolio with Cyclerion Stock |
Cyclerion Therapeutics Company Price To Earning Analysis
Cyclerion Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Cyclerion Therapeutics Price To Earning | (0.59) X |
Most of Cyclerion Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclerion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Cyclerion Therapeutics has a Price To Earning of -0.5885 times. This is 102.28% lower than that of the Biotechnology sector and 111.94% lower than that of the Health Care industry. The price to earning for all United States stocks is 102.05% higher than that of the company.
Cyclerion Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclerion Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclerion Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclerion Therapeutics by comparing valuation metrics of similar companies.Cyclerion Therapeutics is currently under evaluation in price to earning category among its peers.
Cyclerion Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (17.99) % | ||||
| Current Valuation | 5.6 M | ||||
| Shares Outstanding | 3.56 M | ||||
| Shares Owned By Insiders | 32.72 % | ||||
| Shares Owned By Institutions | 12.21 % | ||||
| Number Of Shares Shorted | 17.18 K | ||||
| Price To Earning | (0.59) X | ||||
| Price To Book | 1.05 X | ||||
| Price To Sales | 4.44 X | ||||
| Revenue | 2 M | ||||
| Gross Profit | 2.08 M | ||||
| EBITDA | (3.63 M) | ||||
| Net Income | (3.06 M) | ||||
| Cash And Equivalents | 30.32 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 725 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 2.87 X | ||||
| Cash Flow From Operations | (4.33 M) | ||||
| Short Ratio | 0.51 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Target Price | 4.0 | ||||
| Beta | 1.55 | ||||
| Market Capitalization | 9.24 M | ||||
| Total Asset | 9.57 M | ||||
| Retained Earnings | (267.49 M) | ||||
| Working Capital | 3.5 M | ||||
| Current Asset | 109.19 M | ||||
| Current Liabilities | 18.4 M | ||||
| Net Asset | 9.57 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Tools for Cyclerion Stock
When running Cyclerion Therapeutics' price analysis, check to measure Cyclerion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclerion Therapeutics is operating at the current time. Most of Cyclerion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclerion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclerion Therapeutics' price. Additionally, you may evaluate how the addition of Cyclerion Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |